Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK

Payment Information We Accept Visa, Mastercard, American Express and Discover

 

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Senseonics, Viatris, and Bayer Q1 ’22 Earnings Updates; Novo and Flagship Pioneering Collaboration; First Patient Dosed in Adocia Ph3 BC Lispro Trial

Here is a brief preview of this blast: A series of cardiometabolic-related news items have been observed: Senseonics hosted its Q1 ‘22 earnings call (press release); Novo Nordisk announced a strategic collaboration with Flagship Pioneering for the development of novel research programs in cardiometabolic and rare diseases; Viatris (press release; slides) and Bayer (press release; slides) hosted their respective Q1 ’22 earnings calls; and Adocia announced the first patient has been dosed in its Ph3 BC Lispro program being conducted by partner Tonghua Dongbao (THDB). Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.